Brini Marisa
Department of Biochemistry and Department of Experimental Veterinary Sciences, University of Padua, Viale G. Colombo 3, 35121 Padua, Italy.
Biochem Biophys Res Commun. 2004 Oct 1;322(4):1245-55. doi: 10.1016/j.bbrc.2004.08.029.
Ryanodine receptor (RyR), a homotetrameric Ca2+ release channel, is one of the main actors in the generation of Ca2+ signals that trigger muscle contraction. Three genes encode three isoforms of RyRs, which have tissue-restricted distribution. RyR1 and RyR2 are typical of muscle cells, with RyR1 originally considered the skeletal muscle type and RyR2 the cardiac type. However, RyR1 and RyR2 have recently been found in numerous other cell types, including, for instance, peripheral B and T lymphocytes. In contrast, RyR3 is widely distributed among cells. RyR1 and RyR2 are localized in a specialized portion of the sarcoplasmic reticulum (SR), the terminal cisternae, which is the portion of the SR Ca2+ store that releases Ca2+ to control the process of muscle contraction. A specific role for RyR3 has not yet been established: probably, its co-expression with the other RyR isoforms contributes to qualitatively modulate Ca2+-dependent processes in muscle cells and in neurons. Several mutations in the genes encoding RyR1 and RyR2 have been identified in autosomal dominant diseases of skeletal and cardiac muscle, such as malignant hyperthermia (MH), central core disease (CCD), catecholaminergic polymorphic ventricular tachycardia (CPVT), and arrhythmogenic right ventricular dysplasia type 2 (ARVD2). More recently, CCD cases with recessive inheritance have also been described. MH is a pharmacogenetic disease, but the others manifest as congenital myopathies. Even if their clinical phenotypes are well established, particularly in skeletal muscle, the molecular mechanisms that generate the conditions are not clear. A number of studies on cellular models have attempted to elucidate the molecular defects associated with the different mutations, but the problem of understanding how mutations in the same gene generate such an array of diverse pathological traits and diseases of widely different degrees of severity is still open. This review will consider the molecular and cellular effects of RyR mutations, summarizing recent data in the literature on Ca2+ dysregulation, which may lead to a better understanding of the functioning of RyRs.
兰尼碱受体(RyR)是一种同四聚体Ca2+释放通道,是触发肌肉收缩的Ca2+信号产生过程中的主要参与者之一。三个基因编码三种RyR亚型,它们具有组织限制性分布。RyR1和RyR2是肌肉细胞所特有的,最初认为RyR1是骨骼肌型,RyR2是心脏型。然而,最近在许多其他细胞类型中也发现了RyR1和RyR2,例如外周B淋巴细胞和T淋巴细胞。相比之下,RyR3在细胞中广泛分布。RyR1和RyR2定位于肌浆网(SR)的一个特殊部分,即终池,它是SR Ca2+储存库中释放Ca2+以控制肌肉收缩过程的部分。RyR3的具体作用尚未确定:可能它与其他RyR亚型的共表达有助于定性调节肌肉细胞和神经元中依赖Ca2+的过程。在骨骼肌和心肌的常染色体显性疾病中,如恶性高热(MH)、中央轴空病(CCD)、儿茶酚胺能多形性室性心动过速(CPVT)和致心律失常性右室发育不良2型(ARVD2),已鉴定出编码RyR1和RyR2的基因中的几种突变。最近,也描述了具有隐性遗传的CCD病例。MH是一种药物遗传学疾病,但其他疾病表现为先天性肌病。即使它们的临床表型已经明确,特别是在骨骼肌中,产生这些病症的分子机制仍不清楚。许多关于细胞模型的研究试图阐明与不同突变相关的分子缺陷,但如何理解同一基因中的突变如何产生如此一系列不同严重程度的多样病理特征和疾病的问题仍然没有解决。本综述将考虑RyR突变的分子和细胞效应,总结文献中关于Ca2+调节异常的最新数据,这可能有助于更好地理解RyRs的功能。